Bringing International Vaccine Development Expertise to Nigeria through Partnerships and Tech Transfer

**Novel HIV VLP Based Vaccine**
Induced broadly Neutralizing antibodies in Mice model

**Novel Ebola VLP Based Vaccine**
Highly immunogenic in mice model. Plans are underway to develop a bivalent VLP Ebola

**Novel Cell-based Yellow Fever Vaccine**
Licensed a novel cell based YF vaccine - combines characteristics of DNA and inactivated vaccines. The iDNA YF vaccine induced high neutralizing antibodies in mice. Can be formulated for storage at RT.

**Novel Reassortant Lassa Vaccine**
Licensed a Lassa Candidate Vaccine based on reassortant technology. GMP material is now available for tox study and clinical trials.

**Novel HPV Vaccine**
Developing a trivalent 16,18 and 35 HPV vaccine based on African HPV serotypes. Could protect over 90% of HPV serotypes circulating in Africa based on cross-protections

**Partners:**
Merck KGaA, MilliporeSigma, Technovax LLC, Medigen LLC., Lion’s Head UK, Afreximbank Cairo, FinaBio, ITC Geneva, Bharat Biotech India, Walvax etc